Goldman Sachs
HTGM

Goldman Sachs’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Goldman Sachs’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-122
Closed -$111K – 5809
2018
Q3 		$111K Buy
+122
New +$80.5K ﹤0.01% 5104

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs's HTGM Position: Q4 2018 in Review

Goldman Sachs sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2018, closing a stake of 122 shares — an estimated $111K sold.

Goldman Sachs first reported a position in HTGM in Q3 2018 and held it in 1 quarter. The position peaked at $111K in Q3 2018. 48 funds tracked by Wall St. Rank hold HTGM as of Q4 2018.

  • Goldman Sachs reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Goldman Sachs sold 122 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2018, an estimated $111K.
  • Goldman Sachs first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Goldman Sachs's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $111K in Q3 2018.
  • 48 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.